Glioblastoma is the cancer that killed Sen. John McCain. It’s aggressive and there is no cure. But, researchers at Banner MD Cancer Center in Phoenix have opened enrollment for a Phase 2 clinical trial that has shown some earlier promise.
There are roughly 12, 000 to 14,000 cases of glioblastoma every year in the U.S.
“Despite the most aggressive care we have available now, average survival remains between 14 to 16 months, according to Dr. Joseph Georges, an assistant professor of neurosurgery at the University of Arizona College of Medicine.
He also helped develop this first-of-its kind vaccine more than 10 years ago.
“So with this particular vaccine, we acquire a piece of the patient's tumor during surgery. We make a vaccine specific to the patient's tumor," Georges said.
That vaccine then uses the patient’s own immune system to detect and destroy the tumor.
“And glioblastoma has become very good at tricking the immune system and preventing it from directly targeting and attacking it. So immunotherapies like this vaccine help our bodies own natural immune system detect and destroy the tumor," Georges said.
Georges says Phase 1 showed the vaccine was safe and some patients have surpassed three years of survival, more than doubling typical expectations.
Georges says the Phase 2 trial is expected to take two to three years.
-
On the last day of the Arizona State Fair this fall, Jenna Trybus’ 12-year-old daughter, Lucy, and her dad went — they rode some rides and visited the petting zoo. -
The ordinance would introduce regulations for unpaved country roads that see heavy machinery traffic in order to maintain air quality standards and limit dust emissions. -
The Arizona Hospital and Healthcare Association signed a letter in support of the funding application. Ann-Marie Alameddin, the group’s president and CEO, joined The Show to talk more. -
Americans are more likely to visit their eye doctor than their primary care provider. And that’s one big reason why a company out of California is working with Banner Alzheimer’s Institute in Arizona to develop an eye test that can detect beta amyloid in the retina. -
Researchers at the University of Arizona say a previously unknown population of circulating immune cells play a critical role in fibrosis. Blocking their signals could help treat or prevent the condition.
